Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 19.97% is 11% above its 1-year average of 17.91%, near the high end of its 1-year range (15.86%–19.97%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly EBITDA margin; no daily interpolation.
Limited quarterly history available
EBITDA Margin needs at least three reported quarters before a meaningful chart is shown.
EBITDA MARGIN
19.97%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$787624.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$878396.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$885939.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$888387.00
EBITDA Margin
-148.44%
TTM Avg
-191.64%
3Y Avg
-1422.24%
5Y Avg
-1921.61%
Market Cap
$1.02M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$61819.00
EBITDA Margin
-1762.94%
TTM Avg
-1134.94%
3Y Avg
-792.43%
5Y Avg
-12891.91%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CDT Equity Inc. (CDT) | $707297.00 | 19.97% | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | -148.44% | -191.64% | -1422.24% | -1921.61% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Akanda Corp. (AKAN)vs › | $61819.00 | -1762.94% | -1134.94% | -792.43% | -12891.91% |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.37M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
20.0%
Operating Margin
0.0%
Net Margin
6.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 19.97% |
| 2026-03-29 | 15.86% |
